The biggest change to Good Clinical Practice in nearly a decade is here. ICH adopted the E6(R3) Principles and Annex 1 on 6 January 2025. The EU made it effective in July 2025 and the US FDA published it as final guidance later that year. Regulators worldwide, including in India, are aligning with it.
If you sponsor trials in India – especially trials whose data will be used abroad – E6(R3) is now the standard your study will be judged against. Here is what it means in plain English.
1. Quality by design, not quality by inspection
E6(R2) introduced risk-based monitoring. E6(R3) goes further: quality must be built into the protocol from the start. Sponsors are expected to identify what is critical to quality – the data and processes that truly affect participant safety and the reliability of results – and focus effort there.
What to do: run a documented risk assessment at protocol stage, and revisit it as the study progresses.
2. Proportionality everywhere
The guideline repeatedly asks for approaches that are proportionate to risk. A low-risk nutraceutical study does not need the same level of monitoring as a first-in-human oncology trial. That is good news for smaller sponsors – but only if the reasoning is written down.
What to do: document why your monitoring, data checks and audit plan are right-sized for your trial.
3. Stronger sponsor oversight
E6(R3) makes it clear that sponsors must oversee every service provider – CROs, labs, technology vendors. Signing a contract is not oversight.
What to do: define oversight activities (meetings, metrics, audits) in an oversight plan and keep evidence that you did them.
4. Technology-neutral and data-focused
The new text is written to work for paper, electronic and hybrid trials. It gives detailed attention to data governance: audit trails, access control, system validation and the integrity of data across its whole life cycle.
What to do: ask your vendors for validation evidence, and make sure audit trails are reviewed, not just switched on.
5. Participant-centred conduct
E6(R3) puts more weight on the participant experience – clear consent information, reduced burden and flexibility such as remote consent or visits where appropriate and permitted locally.
What to do: review consent documents and visit schedules from the participant's point of view.
6. Essential records, not just essential documents
The focus shifts from a fixed list of documents to records that allow the trial to be reconstructed and evaluated. Your TMF must tell the story of the study.
What this means in India
Indian trials are governed by the New Drugs and Clinical Trials Rules, 2019 and Indian GCP guidance, and CDSCO has been moving its guidance in line with E6(R3) themes. For global sponsors, sites in India will be inspected against E6(R3) expectations by foreign regulators too.
The practical gap I see most often: sites and smaller CROs are still working with E6(R2)-era SOPs and training. A short gap assessment now can prevent findings later.
Quick E6(R3) readiness checklist
- Is there a documented risk assessment for each study?
- Is the monitoring plan clearly risk-based and justified?
- Is there a written vendor oversight plan with evidence of execution?
- Are computerised systems validated and audit trails reviewed?
- Have site and sponsor staff been trained on E6(R3)?
If you answered "no" or "not sure" to any of these, now is the right time to act.
Need an E6(R3) gap assessment or training for your team or sites? Write to me at anup.cra@gmail.com.
– Anup Kumar, Independent Clinical Research Auditor & Consultant, New Delhi
